Fig. 1.

ATO modulates GLI activity in patients with CRC. (A and B) RNA was extracted from the tumor (A) or associated WBCs (B) of a patient with CRC who received ATO in the clinic. The expression of GLI target genes relative to that of GAPDH was determined by qRT-PCR. Error bars indicate the S.E. of triplicate experiments using one sample. Similar non-normalized data are shown in Supplemental Fig. 1. (C) Summary of GLI target gene expression in the tumors and associated WBCs of a group of patients with CRC who received ATO treatment. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.